Flush with new funding, Quanta plans to launch a study of its portable dialysis device for at-home use. The Alcester, U.K.-based startup received clearance from the Food and Drug Administration in December for its device to be used in a hospital or post-acute setting.
It’s one of several companies looking to enter the market for home dialysis, as established companies, such as DaVita, CVS Health and Fresenius Medical Care look to expand their in-home offerings.
While in-home dialysis can save patients with chronic kidney disease from spending hours each week in dialysis centers, it still requires some training and support, and for patients to even know it’s an option.
Quanta recently raised $245 million in a series D funding round led by Glenview Capital and Novo Holdings. It plans to use the funds to scale up its operations, with a focus on the U.S., in light of its recent clearance. Some of the funds will also go towards a study that the company hopes to use to support the device’s clearance for in-home use.
“We are delighted to attract such a strong syndicate of investors, which represents a clear vote of confidence in our innovative approach to dialysis treatment,” CEO John Milad said in a news release. “Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care.”
Other device competitors are also looking to push further into at-home dialysis. Last year, San Jose-based Outset Medical went public, after getting FDA clearance for at-home use of its device.
Photo: aurielaki, Getty Images